Navigation Links
Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
Date:1/16/2008

etal pain is pain that affects the muscles, ligaments, and tendons. Acute musculoskeletal injuries are common and can occur during sports activities, exercise, or other physical activities. Acute musculoskeletal injuries generally require rapid treatment, which often includes the administration of anti-inflammatory drugs. Optimal topical treatment should relieve acute pain and reduce swelling in the injured area to restore normal movement. In addition, it should be safe and easy to administer.

Pain represents a large and dynamic market in the United States. Oral formulations of NSAIDs currently are marketed worldwide for the treatment of inflammation and pain, including pain due to musculoskeletal injuries, signs and symptoms of osteoarthritis and rheumatoid arthritis, menstrual cramps, headache and other minor aches and pains. While traditional oral NSAIDs are effective, they can cause serious gastrointestinal and other adverse events. Further, the withdrawal of some COX-2 inhibitors has removed a major therapeutic option for patients with multiple moderate and severe forms of pain, resulting in a significant market opportunity. These developments have created a significant need for a localized pain product with a strong safety profile.

About Cerimon Pharmaceuticals

Cerimon Pharmaceuticals, Inc., is a biopharmaceutical company dedicated to developing and commercializing therapeutic products for autoimmune diseases, inflammation and pain. Cerimon believes these new treatment options will enable physicians specialized in treating these conditions to further improve the lives of their patients.

Cerimon currently has two drugs in development. Simulect(R) (basiliximab) entered a Phase IIb study for moderate-to-severe steroid-refractory ulcerative colitis in April 2007. In addition, the Company has now initiated two Phase II/III studies of a topical patch formulation of diclofenac sodium in patients with acute musculoskeletal pain.

Ceri
'/>"/>

SOURCE Cerimon Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cerimon Pharmaceuticals Initiates Phase I Clinical Study of Topical Diclofenac Sodium Patch
2. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
3. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
6. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
7. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
8. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
9. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
10. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
11. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... DIEGO , Nov. 24, 2014  GlySens Incorporated ... two million dollar grant from the National Institute of ... of the National Institutes of Health (NIH).  The grant ... GlySens second generation ICGM™ long term implantable glucose monitoring ... underway, and enrollment is expected to begin before the ...
(Date:11/23/2014)... HAYWARD, Calif. , Nov. 23, 2014 ... today that Paul F. Truex , President and ... the 2014 Annual Piper Jaffray Healthcare Conference. ... rd , at the Palace Hotel in ... Anthera Pharmaceuticals Anthera Pharmaceuticals is a biopharmaceutical ...
(Date:11/22/2014)... de 2014  BioClinica®, Inc., un proveedor líder ... eClinical, ha indicado un aumento de la demanda ... seguimiento basado en el riesgo en los ensayos ... seguimiento basado en el riesgo más allá de ... o cambio de los métodos de seguimiento. Se ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
... PLC ), a company focused on innovative cardiac ... the three,and twelve month periods ended December 31, 2007., ... with,$1,747,000 in the fourth quarter of 2006. The net ... $0.03 per diluted share, compared to net,income of $36,000, ...
... XYOTAX to be reviewed for PS2 first-line non-small cell lung cancer ... ... March 4 Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) announced ... Medicines Agency (EMEA) for,XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of,patients ...
Cached Medicine Technology:PLC Systems Reports Fourth Quarter 2007 Results 2PLC Systems Reports Fourth Quarter 2007 Results 3PLC Systems Reports Fourth Quarter 2007 Results 4PLC Systems Reports Fourth Quarter 2007 Results 5PLC Systems Reports Fourth Quarter 2007 Results 6Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 2Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 3Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 4
(Date:11/24/2014)... 24, 2014 Mental health issues ... They break up families, ruin careers, and generally ... for those that suffer,” says Hardy Nutritionals® ... showing that our specialized nutritional treatments can reverse ... on “Mind Over Matter”, the premiere episode of ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Dr. Michael ... Fertility Center, recently appeared on NBC to discuss egg freezing ... freezing has been trending in the news recently, with new ... procedure for women. , “[The companies] see it ... are on a career hot path.” Says Dr. Kettel. , ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 The ... Market 2006 to 2020 - Asia-Pacific” provides quantitative ... devices market segments: minimally invasive body contouring devices, ... The analysis includes market size data by revenue ... the following countries: China, Japan, South Korea, Australia ...
(Date:11/23/2014)... (HealthDay News) -- The holidays can be a challenge ... can trigger major meltdowns, an expert says. "Holidays ... circumstances, but when you have children with special needs, ... therapy professor at University of the Sciences in Philadelphia, ... to let your hosts or visitors know what special ...
(Date:11/23/2014)... York, NY (PRWEB) November 23, 2014 ... the past month in a federal litigation involving Byetta ... similar diabetes medications, Bernstein Liebhard LLP reports. , ... 566 claims over a class of Type 2 diabetes ... filed in the U.S. District Court, Southern District of ...
Breaking Medicine News(10 mins):Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 2Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 3Health News:Aesthetic Lasers and Energy Devices Market in APAC (China, Japan, South Korea, Australia and India) to 2020 4Health News:Holidays Can Be Sensory Overload for Kids With Autism 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 2Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 3Health News:California Federal Court Overseeing Byetta Lawsuits, Other Incretin Mimetic Claims Adds New Cases in November, Bernstein Liebhard LLP Reports 4
... PHILADELPHIA, Dec. 24 Congressman Chaka Fattah (D-PA) releases the ... reform legislation: , "Senate Democrats deserve our thanks and ... to do, but I am confident that the House and ... the new year we will be sending President Obama a ...
... Today, The U.S. Conference of Mayors (USCM) congratulates the U.S. Senate ... millions of the uninsured. In a historic Christmas Eve session, ... Protection and Affordable Care Act. , "Not since 1963, has ... It is appropriate the most important piece of health ...
... cells generate embryonic-like cells, study finds , THURSDAY, Dec. 24 ... fight the common cold and heal wounds, but the antioxidant ... generate embryonic-like stem cells, new research suggests. , The ... Stem Cell , add to previous research that showed how ...
... , WASHINGTON, Dec. 24 "The Senate,s historic vote ... creation of a transformational national long-term services and supports insurance ... people with disabilities. The Senate bill also includes means by ... acute and long-term problems. It will stimulate innovation in ...
... , , WASHINGTON, Dec. ... critical that this step be accomplished as we continue our journey ... committed to working with Congress to ensure health insurance reform is ... Delgado, President and CEO of the National Alliance for Hispanic Health, ...
... of the Bipartisan Policy Center Report Continue to Encourage Joint ... U.S. Senate Majority Leaders Howard Baker, Tom Daschle and Bob ... and Leaders, Project on the State of American Health Care, ... and Affordable Care Act of 2009 today. , ...
Cached Medicine News:Health News:Senate Action Part of Long Road to Health Care Reform 2Health News:Former Senate Majority Leaders Baker, Daschle and Dole Commend Senate Passage of Health Care Bill 2Health News:Former Senate Majority Leaders Baker, Daschle and Dole Commend Senate Passage of Health Care Bill 3
Inquire...
Inquire...
Inquire...
... a range of 18 Ophthalmic frames ... and producted to the very hightest ... super lightweight Titanium and Beta Titanium ... host of beautifully formed and innovative ...
Medicine Products: